“Global Next-Generation Antibody Therapies market set to grow to $17bn by 2023” says new Visiongain report

25 September 2018
Pharma

Visiongain has launched a new pharma report: Global Next-Generation Antibody Therapies Market Forecast 2018-2028: Antibody-Drug Conjugates, Engineered Antibodies, Bispecific Antibodies, Antibody Fragments & ALPs, Biosimilar Antibodies.

Next-generation antibody therapies are becoming established treatments for haematological malignancies and solid tumours (phase 3) pipelines are relatively sparse, however, with most pipeline candidates in phase 1 or phase 2 of development. Growth will be rapid from the middle of the forecast period as new therapies are approved. New therapies will likely compete with currently marketed monoclonal antibodies, biosimilars, and novel small molecule drugs. Increasing collaboration between biotechnology and big pharma companies will drive pipeline development, which may result in the dominance of a small number of technology platforms, as seen for example in the market for antibody-drug conjugates.

The lead analyst of the report commented "Success for developers of next-generation antibody therapies will depend on a number of factors, including having a technology platform that offers some advantage over standard monoclonal antibodies, the ability to advance a novel therapy through proof of concept, and partnership opportunities with Big Pharma.

Products that offer superior or additional efficacy compared to currently available therapies will be needed in order to compete against existing therapies and the biosimilars that are expected to become available for these therapies in developed markets. Alternatively, targeting new indications and new antigens will expand the potential in the market."

Leading companies featured in the report include Amgen, Inc., GlaxoSmithKline (GSK), Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.), Merck KGaA, Novartis AG, Pfizer, Inc., Roche, Sanofi, Seattle Genetics, Inc., Shire plc

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Big Data Analytics in Healthcare Market Report 2021-2031

Healthcare has never been more personalized and affordable to anyone. Digital consulting applications use artificial intelligence to provide medical advice based on customized medical history record reviews and general medical information derived from big data inferences.

13 May 2021

Read

Visiongain Publishes NGS-Based RNA Sequencing Market Report 2021-2031

The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.

11 May 2021

Read

Visiongain Publishes Single-Use Bioreactors Market Report 2021-2031

Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.

11 May 2021

Read

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever